Bottom line
RYCFX vs FBDIX: the short answer
RYCFX (Biotechnology Fund) and FBDIX (Franklin Biotechnology Discovery Fund) are both mutual funds.
FBDIX is cheaper at 1.01% vs 2.38% — a difference of $137 a year per $10,000 invested.
Over five years, FBDIX returned +5.0% a year vs +3.0% for RYCFX.
FBDIX has a front-end sales load of up to 5.5%; the other does not.
Updated Nov 19, 2026
RYCFX vs FBDIX side by side
| RYCFX | FBDIX | |
|---|---|---|
| Type | Mutual fund | Mutual fund |
| Fund family | Guggenheim | Franklin Templeton |
| Category | Technology Sector | Technology Sector |
| Expense ratio | 2.38% | 1.01% |
| Annual cost per $10k | $238 | $101 |
| 10-yr cost on $10k (prospectus) | $2,763 | $1,728 |
| Max front load | 0% | 5.5% |
| 12b-1 fee | 1% | 0.25% |
| 1-yr return | +28.4% | +43.9% |
| 5-yr return (annualized) | +3.0% | +5.0% |
| 10-yr return (annualized) | +4.8% | +6.4% |
| Best quarter | +28.0% | +29.5% |
| Worst quarter | −22.7% | −24.5% |
| Net assets (fund) | $136.8M | $1.2B |
| Number of holdings | 74 | 126 |
| Portfolio turnover | 75% | 38% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | RYCFX | FBDIX | Difference |
|---|---|---|---|
| 2025 | +29.4% | +52.3% | −22.9% |
| 2024 | −1.7% | +4.0% | −5.7% |
| 2023 | +5.0% | +18.4% | −13.4% |
| 2022 | −13.9% | −12.7% | −1.3% |
| 2021 | +0.8% | −17.7% | +18.5% |
| 2020 | +20.9% | +29.9% | −9.0% |
| 2019 | +23.8% | +34.8% | −11.1% |
| 2018 | −9.9% | −15.7% | +5.8% |
| 2017 | +28.4% | +18.8% | +9.6% |
| 2016 | −20.3% | −17.2% | −3.1% |
Source: Fund prospectus bar charts
Holdings overlap
12 of RYCFX's top 25 holdings also appear in FBDIX's top 25.
| Holding | RYCFX | FBDIX |
|---|---|---|
| Amgen Inc | 5.05% | 4.39% |
| Gilead Sciences Inc | 4.49% | 3.86% |
| Vertex Pharmaceuticals Inc | 4.32% | 3.54% |
| Regeneron Pharmaceuticals Inc | 2.93% | 3.77% |
| Revolution Medicines Inc | 2.48% | 3.01% |
| Insmed Inc | 1.79% | 1.99% |
| Guardant Health Inc | 1.72% | 2.76% |
| Neurocrine Biosciences Inc | 1.52% | 1.82% |
| Argenx Se | 1.48% | 3.62% |
| Jazz Pharmaceuticals Plc | 1.42% | 5.66% |
| Bridgebio Pharma Inc | 1.38% | 1.67% |
| Cytokinetics Inc | 1.35% | 1.24% |
Source: SEC Form N-PORT
RYCFX top 10
- Abbvie Inc — 8.17%
- Amgen Inc — 5.05%
- Gilead Sciences Inc — 4.49%
- Vertex Pharmaceuticals Inc — 4.32%
- Regeneron Pharmaceuticals Inc — 2.93%
- Revolution Medicines Inc — 2.48%
- Alnylam Pharmaceuticals Inc — 2.36%
- Beone Medicines Ltd — 2.17%
- Moderna Inc — 2.15%
- Biogen Inc — 2.13%
FBDIX top 10
- Jazz Pharmaceuticals plc — 5.66%
- Amgen, Inc. — 4.39%
- Gilead Sciences, Inc. — 3.86%
- Regeneron Pharmaceuticals, Inc. — 3.77%
- Argenx SE — 3.62%
- Vertex Pharmaceuticals, Inc. — 3.54%
- Franklin Institutional U.S. Government Money Market Fund — 3.18%
- Revolution Medicines, Inc. — 3.01%
- Guardant Health, Inc. — 2.76%
- Ascendis Pharma A/S — 2.56%
FAQ
What is the difference between RYCFX and FBDIX?
Which is cheaper, RYCFX or FBDIX?
Should I own both RYCFX and FBDIX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.